The psychopharmacologic treatment of personality disorders.
We have reviewed both the rationale for and approaches to the use of psychotropic medications in the treatment of personality disorders. Despite some studies that may provide the seeding crystals around which significant data bases regarding the drug treatment of personality disorders will develop, the pharmacologic treatment of personality disorder remains a clouded area governed more by opinion than fact. Clinicians must still be guided by basic clinical sense regarding the use of medications with these patients. Some questions to ask are the following: Has the patient responded to medications in the past? What are the risks for abuse or self-destructive acting out? What is the risk-to-benefit ratio for the introduction of a drug into a psychotherapeutic situation at a given time? Is hospitalization necessary to assess the potential benefits of medication to the patient while minimizing the potential to act out? Although these guidelines may seem inadequate, clinicians can take some solace in the fact that ongoing studies will lead to better informed psychopharmacologic choices for patients with personality disorders.
D000927:Anticonvulsants / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000987:Antisocial Personality Disorder / Q000503:physiopathology; D001341:Autonomic Nervous System / Q000503:physiopathology; D001883:Borderline Personality Disorder / Q000188:drug therapy; D004644:Emotions / Q000187:drug effects; D006801:Humans; D007175:Impulsive Behavior / Q000187:drug effects; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D008774:Methylphenidate / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010554:Personality Disorders / Q000188:drug therapy*; D012569:Schizotypal Personality Disorder / Q000175:diagnosis / Q000188:drug therapy
D000927:Anticonvulsants; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D008774:Methylphenidate; D016651:Lithium Carbonate; D008094:Lithium